|Jump to:||Authorized Access|||||Attribution|||||Authorized Requests|
- Study Description
Startup of Framingham Heart Study. Cardiovascular disease (CVD) is the leading cause of death and serious illness in the United States. In 1948, the Framingham Heart Study (FHS) -- under the direction of the National Heart Institute (now known as the National Heart, Lung, and Blood Institute, NHLBI) -- embarked on a novel and ambitious project in health research. At the time, little was known about the general causes of heart disease and stroke, but the death rates for CVD had been increasing steadily since the beginning of the century and had become an American epidemic.
The objective of the FHS was to identify the common factors or characteristics that contribute to CVD by following its development over a long period of time in a large group of participants who had not yet developed overt symptoms of CVD or suffered a heart attack or stroke.
Design of Framingham Heart Study. In 1948, the researchers recruited 5,209 men and women between the ages of 30 and 62 from the town of Framingham, Massachusetts, and began the first round of extensive physical examinations and lifestyle interviews that they would later analyze for common patterns related to CVD development. Since 1948, the subjects have returned to the study every two years for an examination consisting of a detailed medical history, physical examination, and laboratory tests, and in 1971, the study enrolled a second-generation cohort -- 5,124 of the original participants' adult children and their spouses -- to participate in similar examinations. The second examination of the Offspring cohort occurred eight years after the first examination, and subsequent examinations have occurred approximately every four years thereafter. In April 2002 the Study entered a new phase: the enrollment of a third generation of participants, the grandchildren of the original cohort. The first examination of the Third Generation Study was completed in July 2005 and involved 4,095 participants. Thus, the FHS has evolved into a prospective, community-based, three generation family study. The FHS is a joint project of the National Heart, Lung and Blood Institute and Boston University.
Research Areas in the Framingham Heart Study. Over the years, careful monitoring of the FHS population has led to the identification of the major CVD risk factors -- high blood pressure, high blood cholesterol, smoking, obesity, diabetes, and physical inactivity -- as well as a great deal of valuable information on the effects of related factors such as blood triglyceride and HDL cholesterol levels, age, gender, and psychosocial issues. Risk factors have been identified for the major components of CVD, including coronary heart disease, stroke, intermittent claudication, and heart failure. It is also clear from research in the FHS and other studies that substantial subclinical vascular disease occurs in the blood vessels, heart and brain that precedes clinical CVD. With recent advances in technology, the FHS has enhanced its research capabilities and capitalized on its inherent resources by the conduct of high resolution imaging to detect and quantify subclinical vascular disease in the major blood vessels, heart and brain. These studies have included ultrasound studies of the heart (echocardiography) and carotid arteries, computed tomography studies of the heart and aorta, and magnetic resonance imaging studies of the brain, heart, and aorta. Although the Framingham cohort is primarily white, the importance of the major CVD risk factors identified in this group have been shown in other studies to apply almost universally among racial and ethnic groups, even though the patterns of distribution may vary from group to group. In the past half century, the Study has produced approximately 1,200 articles in leading medical journals. The concept of CVD risk factors has become an integral part of the modern medical curriculum and has led to the development of effective treatment and preventive strategies in clinical practice.
In addition to research studies focused on risk factors, subclinical CVD and clinically apparent CVD, Framingham investigators have also collaborated with leading researchers from around the country and throughout the world on projects involving some of the major chronic illnesses in men and women, including dementia, osteoporosis and arthritis, nutritional deficiencies, eye diseases, hearing disorders, and chronic obstructive lung diseases.
Genetic Research in the Framingham Heart Study. While pursuing the Study's established research goals, the NHLBI and the Framingham investigators has expanded its research mission into the study of genetic factors underlying CVD and other disorders. Over the past two decades, DNA has been collected from blood samples and from immortalized cell lines obtained from Original Cohort participants, members of the Offspring Cohort and the Third Generation Cohort. Several large-scale genotyping projects have been conducted in the past decade. Genome-wide linkage analysis has been conducted using genotypes of approximately 400 microsatellite markers that have been completed in over 9,300 subjects in all three generations. Analyses using microsatellite markers completed in the original cohort and Offspring cohorts have resulted in over 100 publications, including many publications from the Genetics Analysis Workshop 13. Several other recent collaborative projects have completed thousands of SNP genotypes for candidate gene regions in subsets of FHS subjects with available DNA. These projects include the Cardiogenomics Program of the NHLBI's Programs for Genomics Applications, the genotyping of ~3000 SNPs in inflammation genes, and the completion of a genome-wide scan of 100,000 SNPs using the Affymetrix 100K Genechip.
100K Genome-Wide Association Study and Results Browser. A subset of 1345 adult participants (original cohort and offspring) of the largest 310 pedigrees in the FHS, many biologically related, was genotyped with the 100K Affymetrix GeneChip. These genotypes were used to assess their contribution to a wide range of traits collected in FHS over 59 years of follow up, including: cardiovascular risk factors and biomarkers; subclinical and clinical cardiovascular disease; cancer and longevity traits; and traits in pulmonary, sleep, neurology, renal, and bone domains. We conducted genome-wide variance components linkage and population-based and family-based association tests. An overview manuscript as well as 17 manuscripts describing the unreplicated results of analyses of the various phenotypes were published in a supplement of BMC Medical Genetics in September 2007. A link to the full disclosure results of these analyses are available through dbGaP on the Associated Analyses section on the right side of this page.
Framingham Heart Study SHARe Genome-Wide Association Study. In 2007, the FHS entered a new phase with the conduct of genotyping for the FHS SHARe (SNP Health Association Resource) project, for which genotyping is conducted using approximately 550,000 SNPs (Affymetrix 500K mapping array plus Affymetrix 50K supplemental array) in over 9,300 subjects from the three generations of subjects (including over 900 families). The SHARe database is housed at NCBI's dbGaP and will contain all 550,000 SNPs as well as SNP and microsatellite genotyping conducted previously in the FHS. The phenotype database will contain a vast array of phenotype information available in all three generations. These will include the quantitative measures of the major risk factors such as systolic blood pressure, total and HDL cholesterol, fasting glucose, and cigarette use, as well as anthropomorphic measures such as body mass index, biomarkers such as fibrinogen and CRP, and electrocardiography measures such as the QT interval. Many of these measures have been collected repeatedly in the original and Offspring cohorts. Also included in the SHARe database will be an array of recently collected biomarkers, subclinical disease imaging measures, clinical CVD outcomes as well as an array of ancillary studies.
The unflagging commitment of the research participants in the NHLBI FHS has made more than a half century of research success possible. For decades, the FHS has made its data and DNA widely available to qualified investigators throughout the world through the Limited Access Datasets and the FHS DNA Committee, and the SHARe database will continue that tradition by allowing access to qualified investigators who agree to the requirements of data access. With the SHARe database, we continue with an ambitious research agenda and look forward to new discoveries in the decades to come.
- Study Weblink: The Framingham Heart Study
- Study Type: Longitudinal
Number of study subjects that have individual level data available through Authorized Access: 14261
- Authorized Access
- Publicly Available Data (Public ftp)
Connect to the public download site. The site contains release notes and manifests. If available, the site also contains data dictionaries, variable summaries, documents, and truncated analyses.
- Study Inclusion/Exclusion Criteria
A description of the Design of the Original Cohort can be found at Dawber TR, Meadors GF, and Moore FEJ. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health 1951; 41:279-86.
A description of the Design of the Offspring Cohort can be found at Feinleib M, Kannel WB, Garrison RJ, et al. (1975) The Framingham Offspring Study. Design and preliminary data. Prev Med 4:518-25.
A description of the Design of the Third Generation Cohort can be found at Splansky GL et al. The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: Design, Recruitment, and Initial Examination. Am J Epidemioly 2007 Mar 19 [Epub ahead of print].
- Molecular Data
Type Source Platform Number of Oligos/SNPs SNP Batch Id Comment Whole Genome Genotyping Affymetrix Mapping50K_Hind240 57449 33750 Affymetrix 100K Set comprises Mapping50K_Hind240 and Mapping50K_Xba240 Arrays Whole Genome Genotyping Affymetrix Mapping50K_Xba240 58960 33751 Affymetrix 100K Set comprises Mapping50K_Hind240 and Mapping50K_Xba240 Arrays Whole Genome Genotyping Affymetrix Mapping250K_Nsp 262264 33767 Affymetrix 500K Set comprises Mapping250K_Nsp and Mapping250K_Sty Arrays Whole Genome Genotyping Affymetrix Mapping250K_Sty 238304 33766 Affymetrix 500K Set comprises Mapping250K_Nsp and Mapping250K_Sty Arrays Whole Genome Genotyping Affymetrix HuGeneFocused50K_Affy 49214 52071
- Study History
Research milestones of the Framingham Heart Study can be found at http://www.framinghamheartstudy.org/about/milestones.html.
The Original cohort began Exam 1 in 1948 (9/1948 - 4/1953) and has continued with biennial examinations to the present.
The Offspring cohort began Exam 1 in 1971 (8/1971 - 9/1975) and has on average been examined every 3 to 4 years since enrollment. However, there was an eight year window between exam 1 and exam 2. Exam 7 was performed from 9/1998 - 10/2001.
The Generation 3 cohort Exam 1 was performed 4/2002 - 7/2005.
Examinations continue to be performed.
- Selected publications
- Diseases/Traits Related to Study (MESH terms)
- Authorized Data Access Requests
- Study Attribution
- The National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
- Boston University, Boston, MA, USA
Acknowledgement Statement: Please cite/reference the use of dbGaP data by including the dbGaP accession phs000007.v2.p1. Additionally, use this statement to acknowledge the submitter(s) of this study.